Mind Medicine (MindMed) (OTCMKTS:MMEDF) Trading Down 3.2% – Should You Sell?

Shares of Mind Medicine (MindMed) Inc. (OTCMKTS:MMEDF) traded down 3.2% on Thursday . The stock traded as low as $22.62 and last traded at $23.08. 1,812,993 shares were traded during mid-day trading, a decline of 46% from the average session volume of 3,376,665 shares. The stock had previously closed at $23.84.

Mind Medicine (MindMed) Stock Down 3.2%

The company has a 50 day simple moving average of $18.81 and a two-hundred day simple moving average of $15.29.

Mind Medicine (MindMed) Company Profile

Mind Medicine (MindMed) is a clinical-stage biotechnology company focused on developing innovative therapies derived from psychedelic compounds to address mental health disorders and addiction. The company’s research pipeline includes programs based on LSD, psilocybin and 18-methoxycoronaridine (18-MC), targeting conditions such as anxiety disorders, attention-deficit/hyperactivity disorder (ADHD) and opioid dependence. MindMed seeks to build a portfolio of drug candidates that combine pharmacological efficacy with optimized dosing regimens and delivery methods.

Founded in 2019 and headquartered in New York City, MindMed operates research facilities in North America and Europe, collaborating with academic institutions and medical centers to advance its clinical trials.